Akèy › Kansè tete negatif triple › Indiana › Indianapolis
Etid klinik pou Kansè tete negatif triple nan Indianapolis, IN
9 etid pou Kansè tete negatif triple ap chèche patisipan nan sit nan ak bò kote Indianapolis (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Ap rekriteFaz 1
- IU Simon Cancer Center, Indianapolis
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Ap rekriteFaz 3
- Franciscan Health ( Site 0077), Indianapolis
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Ap rekriteFaz 3
- Franciscan Health Indianapolis, Indianapolis
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
Ap rekriteFaz 2
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
- Sidney and Lois Eskenazi Hospital, Indianapolis
A Study of LY4175408 in Participants With Advanced Cancer
Ap rekriteFaz 1
- Community Health Network, Indianapolis
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Ap rekriteFaz 1
- Community Health Network, Inc. /ID# 243011, Indianapolis
A Study of Tetrathiomolybdate (TM) Plus Capecitabine
Ap rekriteFaz 1/2
- Indiana University Simon Cancer Center, Indianapolis
NearWave Optical Molecular Monitoring
Ap rekrite
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Ap rekriteFaz 1/2
- Community Health Network, Indianapolis
Etid Kansè tete negatif triple nan lòt vil
- Houston, TX42 etid
- New York City, NY31 etid
- Nashville, TN28 etid
- Los Angeles, CA27 etid
- Boston, MA26 etid
- San Antonio, TX23 etid
- St. Louis, MO21 etid
- Arlington, VA20 etid
- Atlanta, GA20 etid
- Dallas, TX18 etid
- Chicago, IL16 etid
- Columbus, OH16 etid
Lòt etid nan Indianapolis
- Kansè Poumon ki pa ti selil32 etid
- Kansè (tout kalite)24 etid
- Ensifizyans kadyak23 etid
- Obèsite20 etid
- Kansè nan tete20 etid
- Kansè Metastatik19 etid
- Kansè kolorektal18 etid
- Kansè ovè17 etid
- Maladi kadyovaskilè17 etid
- Kansè poumon16 etid
- Dyabèt tip 114 etid
- Kansè Endomèt14 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.